the Commission's TDD terminal on 202–205–1810. Persons with mobility impairments who will need special assistance in gaining access to the Commission should contact the Office of the Secretary at 202–205–2000. General information concerning the Commission may also be obtained by accessing its internet server (*https://www.usitc.gov*). The public record for this investigation may be viewed on the Commission's electronic docket (EDIS) at *https://edis.usitc.gov.*

SUPPLEMENTARY INFORMATION:

Background.—These investigations are being instituted, pursuant to sections 703(a) and 733(a) of the Tariff Act of 1930 (19 U.S.C. 1671b(a) and 1673b(a)), in response to a petition filed on February 4, 2019, by American Institute of Steel Construction, LLC, Chicago, IL.

For further information concerning the conduct of these investigations and rules of general application, consult the Commission's Rules of Practice and Procedure, part 201, subparts A and B (19 CFR part 201), and part 207, subparts A and B (19 CFR part 207).

Participation in the investigations and public service list.—Persons (other than petitioners) wishing to participate in the investigations as parties must file an entry of appearance with the Secretary to the Commission, as provided in sections 201.11 and 207.10 of the Commission's rules, not later than seven days after publication of this notice in the **Federal Register**. Industrial users and (if the merchandise under investigation is sold at the retail level) representative consumer organizations have the right to appear as parties in Commission antidumping duty and countervailing duty investigations. The Secretary will prepare a public service list containing the names and addresses of all persons, or their representatives, who are parties to these investigations upon the expiration of the period for filing entries of appearance.

Limited disclosure of business proprietary information (BPI) under an administrative protective order (APO) and BPI service list.—Pursuant to section 207.7(a) of the Commission's rules, the Secretary will make BPI gathered in these investigations available to authorized applicants representing interested parties (as defined in 19 U.S.C. 1677(9)) who are parties to the investigations under the APO issued in the investigations, provided that the application is made not later than seven days after the publication of this notice in the **Federal Register**. A separate service list will be maintained by the Secretary for those parties authorized to receive BPI under the APO.

Conference.—The Commission's Director of Investigations has scheduled a conference in connection with these investigations for 9:30 a.m. on Monday, February 25, 2019, at the U.S. International Trade Commission Building, 500 E Street SW, Washington, DC. Requests to appear at the conference should be emailed to *preliminaryconferences@usitc.gov* (DO NOT FILE ON EDIS) on or before February 21, 2019. Parties in support of the imposition of countervailing and antidumping duties in these investigations and parties in opposition to the imposition of such duties will each be collectively allocated one hour within which to make an oral presentation at the conference. A nonparty who has testimony that may aid the Commission's deliberations may request permission to present a short statement at the conference.

Written submissions.—As provided in sections 201.8 and 207.15 of the Commission's rules, any person may submit to the Commission on or before February 28, 2019, a written brief containing information and arguments pertinent to the subject matter of the investigations. Parties may file written testimony in connection with their presentation at the conference. All written submissions must conform with the provisions of section 201.8 of the Commission's rules; any submissions that contain BPI must also conform with the requirements of sections 201.6, 207.3, and 207.7 of the Commission's rules. The Commission's Handbook on E-Filing, available on the Commission's website at *https://edis.usitc.gov,* elaborates upon the Commission's rules with respect to electronic filing.

In accordance with sections 201.16(c) and 207.3 of the rules, each document filed by a party to the investigations must be served on all other parties to the investigations (as identified by either the public or BPI service list), and a certificate of service must be timely filed. The Secretary will not accept a document for filing without a certificate of service.

Certification.—Pursuant to section 207.3 of the Commission's rules, any person submitting information to the Commission in connection with these investigations must certify that the information is accurate and complete to the best of the submitter's knowledge. In making the certification, the submitter will acknowledge that any information that it submits to the Commission during these investigations may be disclosed to and used: (i) By the Commission, its employees and Offices, and contract personnel (a) for developing or maintaining the records of these or related investigations or reviews, or (b) in internal investigations, audits, reviews, and evaluations relating to the programs, personnel, and operations of the Commission including under 5 U.S.C. Appendix 3; or (ii) by U.S. government employees and contract personnel, solely for cybersecurity purposes. All contract personnel will sign appropriate nondisclosure agreements.

Authority: These investigations are being conducted under authority of title VII of the Tariff Act of 1930; this notice is published pursuant to section 207.12 of the Commission's rules.

By order of the Commission.

Issued: February 5, 2019.

Lisa Barton,

Secretary to the Commission.

[FR Doc. 2019–01730 Filed 2–8–19; 8:45 am]

BILLING CODE 7020–02–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–392]

Importer of Controlled Substances Application: PerkinElmer, Inc.

ACTION: Notice of application.

DATES: Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before March 13, 2019. Such persons may also file a written request for a hearing on the application on or before March 13, 2019.

ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of

the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Assistant Administrator of the DEA Diversion Control Division (''Assistant Administrator'') pursuant to section 7 of 28 CFR part 0, appendix to subpart R.

In accordance with 21 CFR 1301.34(a), this is notice that on December 4, 2018, PerkinElmer, Inc., 120 East Dedham Street, Boston, Massachusetts 02118–2852 applied to be registered as an importer of the following basic classes of controlled substances:

Controlled substance	Drug code	Schedule
Lysergic acid diethylamide.	7315	I
Thebaine	9333	II

The company plans to import the listed controlled substances in bulk for manufacturing wherein the controlled substances will be labeled with a radioactive tracer compound and sold for research purposes to its customers. Thebaine (9333) will be used to manufacture the derivative Diprenorphine.

Dated: February 4, 2019.

John J. Martin,

Assistant Administrator.

[FR Doc. 2019–01848 Filed 2–8–19; 8:45 am]

BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Robert T. Perez, M.D.; Decision and Order

On September 28, 2018, the Assistant Administrator, Diversion Control Division, Drug Enforcement Administration (DEA), issued an Order to Show Cause to Robert T. Perez, M.D. (Registrant), of Santa Ana, California. The Show Cause Order proposed the revocation of Registrant's DEA Certificate of Registration No. BP4317740 on the ground that he does ''not have authority to handle controlled substances in the State of California, the [S]tate in which [he] is registered with the DEA.'' Appendix (App.) 1 (Order to Show Cause) to Government's Request for Final Agency Action (RFAA), at 1 (citing 21 U.S.C. 823(f), 824(a)(3)).

With respect to the Agency's jurisdiction, the Show Cause Order alleged that Registrant is the holder of Certificate of Registration No. BP4317740, pursuant to which he is authorized to dispense controlled substances as a practitioner in schedules II through V, at the registered address of 1420 E. Edinger Ave., Suite 123, Santa Ana, California. *Id.* The Order also alleged that this registration does not expire until March 31, 2019. *Id.*

Regarding the substantive grounds for the proceeding, the Show Cause Order alleged that on or about August 27, 2018, the Medical Board of California (MBC) issued ''an Order On Noticed Petition For Order of Interim Suspension'' (hereinafter ''Interim Order'') that ''suspended'' Registrant's ''authority to prescribe and administer controlled substances in the State of California, the [S]tate in which [he] is registered with the DEA.'' *Id.* at 2. The Show Cause Order more specifically alleged that the Interim Order stated that Registrant ''shall not '[p]ossess, order, purchase, receive, prescribe, furnish, administer, or otherwise distribute controlled substances or dangerous drugs as defined by federal or state law.'' *Id.* As a result, the Show Cause Order alleged that ''DEA must revoke [his] registration . . . based upon [his] lack of authority to handle controlled substances in the State of California.'' *Id.* (citing 21 U.S.C. 824(a)(3)). *Id.*

The Show Cause Order notified Registrant of (1) his right to request a hearing on the allegations or to submit a written statement in lieu of a hearing, (2) the procedure for electing either option, and (3) the consequence for failing to elect either option. *Id.* at 2–3. (citing 21 CFR 1301.43). The Order also notified Registrant of his right to submit a corrective action plan. *Id.* at 3–4 (citing 21 U.S.C. 824(c)(2)(C)).

With respect to service, a Diversion Investigator (DI) with DEA's Los Angeles Field Division executed a Declaration on January 8, 2019 stating that she ''learned that [Registrant] was incarcerated at Santa Ana Jail located in Santa Ana, CA.'' App. 10 (Declaration of DI) to RFAA, at 1. As a result, the DI stated that on October 16, 2018, she ''personally served a copy of the [Show Cause Order] on [Registrant] at the prison.'' *Id.* The Declaration also attached DEA Form 12 Receipt for Cash or Other Items bearing ''Registrant's signature confirming his receipt'' of the Show Cause Order on October 16, 2018. *Id.* at 2; Attachment A to App. 10, at 1.

On January 17, 2019, the Government forwarded its Request for Final Agency Action and evidentiary record to my Office. In its Request, the Government represents that more than 30 days have passed since Registrant had been served and that ''DEA has not received a request for hearing or any other reply from him.'' RFAA, at 5. Based on the Government's representation and the record, I find that more than 30 days have passed since the Order to Show Cause was served on the Registrant, and he has neither requested a hearing nor submitted a written statement in lieu of a hearing. *See* 21 CFR 1301.43(d). Accordingly, I find that Registrant has waived his right to a hearing or to submit a written statement and issue this Decision and Order based on relevant evidence submitted by the Government. *See id.* I make the following findings.

Findings of Fact

Registrant is the holder of DEA Certificate of Registration No. BP4317740, pursuant to which he is authorized to dispense controlled substances in schedules II through V as a practitioner at the registered address of 1420 E. Edinger Ave., Suite 123, Santa Ana, California. App. 2 (Certification of Registration Status) to Govt. Mot., at 1. This registration does not expire until March 31, 2019. *Id.*

Registrant is also the holder of California Physician's and Surgeon's License No. G80178, which was issued to him in 1994 by the MBC. App. 8 to Govt. Mot., at 2. However, on August 27, 2018, an Administrative Law Judge of the MBC issued an Interim Order suspending Registrant's medical license after determining that, under California law, he was ''mentally incompetent to practice medicine safely'' and that ''[p]ermitting [Registrant] to continue to engage in the unrestricted practice of medicine will endanger the public health, safety and welfare.'' *Id.* at 7–8.[1] Among other things, the Interim Order stated that, pending a full administrative determination, Registrant ''shall not'' ''[p]ractice or attempt to practice any aspect of medicine in the

[1] The California ALJ issued the Interim Order after considering the allegations set forth in multiple Accusations that the MBC's Executive Director filed with the MBC from 2015–2018 alleging that Registrant, *inter alia,* (1) engaged in dishonest acts toward a female patient; (2) failed to maintain adequate and accurate records; (3) engaged in unprofessional conduct; (4) engaged in sexual misconduct and unprofessional misconduct related to Registrant's romantic relationship with a female patient who subsequently became his wife; and (5) failed to participate in professional and ethical courses and to provide MBC-mandated quarterly declarations. App. 8 to RFAA, at 2–7; *see also* Apps. 3–7 to RFAA.